ReviewGastroenterology research and practice2015
Diagnosis of Irritable Bowel Syndrome: Role of Potential Biomarkers.
Review in Gastroenterology research and practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Biomarkers in Irritable Bowel Syndrome: Bridging Gut-Brain Mechanisms to Precision Care.Current gastroenterology reports · 2026Review
- Emerging Therapeutic Approaches for Modulating the Intestinal Microbiota.Pharmaceutics · 2026Review
- Irritable bowel syndrome (IBS) among Lebanese adults: unidentified IBS and associated factors.BMC public health · 2023Article
- Irritable Bowel Syndrome: Prevalence and Determinants Among Adults in the Makkah Region, Saudi Arabia.Cureus · 2023Article
- Nutritional Status and Selected Adipokines in Children with Irritable Bowel Syndrome.Nutrients · 2022Article
- Fecal Calprotectin for Small Bowel Crohn's Disease: Is It a Cutoff Issue?Diagnostics (Basel, Switzerland) · 2022Article
- Usefulness of Machine Learning-Based Gut Microbiome Analysis for Identifying Patients with Irritable Bowels Syndrome.Journal of clinical medicine · 2020Article
- Effects of Cognitive Behavior Therapy on Heart Rate Variability in Young Females with Constipation-predominant Irritable Bowel Syndrome: A Parallel-group Trial.Journal of neurogastroenterology and motility · 2017Article
- A novel turbidimetric immunoassay for fecal calprotectin optimized for routine chemistry analyzers.Journal of clinical laboratory analysis · 2017Article
- Hippocampal AMPARs involve the central sensitization of rats with irritable bowel syndrome.Brain and behavior · 2017Article
- Diarrhea-predominant irritable bowel syndrome: creation of an electronic version of a patient-reported outcome instrument by conversion from a pen-and-paper version and evaluation of their equivalence.Patient related outcome measures · 2017Article
- Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome?BMC gastroenterology · 2016Article
- Irritable bowel syndrome among nurses working in King Abdulaziz University Hospital, Jeddah, Saudi Arabia.The Libyan journal of medicine · 2016Article
- Dumping Syndrome: A Review of the Current Concepts of Pathophysiology, Diagnosis, and Treatment.Digestive diseases and sciences · 2016Review
- The prevalence of irritable bowel syndrome among Saudi population in Riyadh by use of Rome IV criteria and self-reported dietary restriction.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome is a disorder diagnosed on symptom-based criteria without inclusion of any objective parameter measurable by known diagnostic methods. Heterogeneity of the disorder and overlapping with more serious organic diseases increase uncertainty for the physician's work and increase the cost of confirming the diagnosis. This paper is an attempt to summarize the efforts to find adequate biomarkers for irritable bowel syndrome, which should shorten the time to diagnosis and reduce the cost. Most of the reviewed papers were observational studies from secondary care institutions. Since publication of the Rome III criteria in 2006, most recent studies use these for the recruitment of IBS patients. This is a positive step forward as future studies should use the same criteria, facilitating comparison of their results. Among the studied biomarkers, most evidence is provided for fecal calprotectin. Cutoff values for fecal calprotectin have still to be investigated prior to inclusion in the irritable bowel syndrome diagnostic algorithm.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.